ReLeave is made up of compassionate and knowledgeable professionals whose goal is to provide exemplary patient care that requires working with only the best healthcare partners. They help incorporate cannabis into the patient’s full medical treatment plans and work with medical cannabis providers such as Ayurcann to ensure their patients receive world-class advice of exceptional value and the right medical cannabis products are prescribed for their needs.
The terms of the agreement provide that ReLeave will send medical cannabis patients to Ayurcann as part of a patient education agreement. Ayurcann will work with patients to educate them about their available offerings and to help them choose appropriate products.
“We seek to work with the industry leaders to work with and improve cannabis education to provide the best possible value, national coverage while expanding our offering of the best domestic and international brands of THC and CBD based products for Patient makes Ayurcann and the Ayurcann marketplace a leader in the industry, “commented Igal Sudman, CEO of Ayurcann. “
“ReLeave began at a very uncertain time that gave us the opportunity to make healthcare different and more patient-centric. As the world changes around us, we strive to improve patient care and work with Ayurcann and the The Ayurcann Marketplace Platform will allow us to outperform Greg Benson, CEO. “
About Ayurcann Holdings Corp .:
Ayurcann is a leading provider of post-harvest solutions focusing on the provision and development of custom processes and pharmaceutical products for the adult and medical cannabis industries in Canada. Ayurcann is focused on becoming the partner of choice for leading Canadian cannabis brands by providing world-class, proprietary services such as ethanol extraction, formulation, product development and custom manufacturing.
About ReLeave Therapeutics:
ReLeave is a team of people who have worked in the medical cannabis field from the very beginning. We are made up of empathetic and knowledgeable experts whose goal is to help people. The ReLeave team supports our doctors with patient admission, follow-up care and education. We help incorporate cannabis into the patient’s full medical treatment plan by working directly with the patient’s existing health care professionals. We believe that teamwork leads to better health outcomes, and building a referral-based practice allows us to work more effectively with patients’ GPs.
Neither the Canadian Securities Exchange nor its regulatory services provider has verified or accepts responsibility for the adequacy or accuracy of this press release.
Certain statements in this press release constitute forward-looking information or statements (collectively, “forward-looking statements”), including those that are identified by the expressions “anticipate,” “believe,” “plan,” “estimate,” “expect”. , “intend”, “may”, “should” and similar expressions insofar as they relate to the company or its management. The forward-looking statements are not historical facts, but reflect current expectations with regard to future results or events. This press release contains forward-looking statements, including, but not limited to, statements regarding the company’s expansion plans and future production capacity. These forward-looking statements are based on current expectations and various estimates, factors and assumptions and involve known and unknown risks, uncertainties and other factors.
Forward-looking statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Factors that could cause actual results to differ materially from those expressed in forward-looking statements include, but are not limited to, the lack of regulatory approval, the ability to increase production at the Company’s facilities, the continued availability of capital and financing as well as general economic, market or business conditions. Forward-looking statements in this press release are expressly restricted by this cautionary statement. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that could cause actual results, performance or achievements to differ materially from those implied in such statements. Although such statements are based on reasonable assumptions made by management, there can be no guarantee that the statements will prove to be correct or that management’s expectations or assessments of future developments, circumstances or results will materialize. Additionally, while the company has attempted to identify important risks, uncertainties, and factors that could cause actual results to differ materially, there may be others that cause results not to be as expected, estimated or intended. and such changes can be material. Public health crises, including the ongoing novel coronavirus (COVID-19) pandemic, could have a significant economic and geopolitical impact that could adversely affect the company’s business, financial condition, and / or results of operations. The company assumes no responsibility to update or revise any forward-looking information to reflect new events or circumstances, except as required by law. Readers are cautioned not to place undue reliance on any forward-looking statements made by the company.
SOURCE Ayurcann Holdings Corp.
For More Information: Please Contact: Igal Sudman, Chairman, Chief Executive Officer, Ayurcann Holdings Corp., Tel: 905-492-3322, Email: [email protected]; Investor Relations: Ryan Bilodeau, Tel: 416-910-1440, Email: [email protected]